By Denny Jacob
Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes.
The biopharmaceutical company said on Friday the study was discontinued due to futility based on a planned analysis. Gilead said it recommends discontinuing treatment with magrolimab in patients with myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow don’t mature or become healthy blood cells.
The company said the safety data seen in the study is consistent with the known magrolimab profile and adverse events that are typical in this patient population.
Gilead said magrolimab is an immunotherapy with a clinical development program spanning 10 potential indications, including ongoing trials in solid tumors and two pivotal trials. One of two trials is a study in acute myeloid leukemia with TP53 mutations and another in first-line, unfit acute myeloid leukemia.
Write to Denny Jacob at [email protected]
Read the full article here
